UBS Group’s Sierra Oncology, Inc. Common Stock SRRA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q3 | – | Sell |
-1,006
| Closed | -$55K | – | 11829 |
|
|
2022
Q2 | $55K | Buy |
+1,006
| New | +$52.8K | ﹤0.01% | 5849 |
|
|
2020
Q1 | – | Sell |
-1,435
| Closed | -$20K | – | 8610 |
|
|
2019
Q4 | $20K | Buy |
1,435
+461
| +47% | +$6.01K | ﹤0.01% | 6889 |
|
|
2019
Q3 | $15K | Buy |
974
+789
| +426% | +$15.1K | ﹤0.01% | 6922 |
|
|
2019
Q2 | $4K | Buy |
+185
| New | +$8.96K | ﹤0.01% | 7481 |
|
|
2019
Q1 | – | Sell |
-1,159
| Closed | -$61K | – | 8363 |
|
|
2018
Q4 | $61K | Sell |
1,159
-3,711
| -76% | -$237K | ﹤0.01% | 5936 |
|
|
2018
Q3 | $331K | Sell |
4,870
-714
| -13% | -$64.8K | ﹤0.01% | 4692 |
|
|
2018
Q2 | $661K | Buy |
5,584
+4,239
| +315% | +$425K | ﹤0.01% | 4113 |
|
|
2018
Q1 | $111K | Buy |
+1,345
| New | +$153K | ﹤0.01% | 5156 |
|
|
2017
Q4 | – | Sell |
-128
| Closed | -$8K | – | 8210 |
|
|
2017
Q3 | $8K | Buy |
+128
| New | +$7.51K | ﹤0.01% | 7022 |
|
|
2017
Q2 | – | Sell |
-73
| Closed | -$4K | – | 8114 |
|
|
2017
Q1 | $4K | Buy |
+73
| New | +$4.24K | ﹤0.01% | 7112 |
|
|
2016
Q3 | – | Sell |
-104
| Closed | -$8K | – | 8052 |
|
|
2016
Q2 | $8K | Buy |
+104
| New | +$19.8K | ﹤0.01% | 6920 |
|
|
2015
Q4 | – | Sell |
-10
| Closed | -$8K | – | 8657 |
|
|
2015
Q3 | $8K | Buy |
+10
| New | +$11.3K | ﹤0.01% | 7437 |
|
Other funds holding SRRA
UBS Group's SRRA Position: Q3 2022 in Review
UBS Group sold out of Sierra Oncology, Inc. Common Stock (SRRA) in Q3 2022, closing a stake of 1,006 shares — an estimated $55K sold.
UBS Group first reported a position in SRRA in Q3 2015 and held it in 12 quarters. The position peaked at $661K in Q2 2018. 1 fund tracked by Wall St. Rank holds SRRA as of Q3 2022.
- UBS Group reported no remaining Sierra Oncology, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
- UBS Group sold 1,006 Sierra Oncology, Inc. Common Stock shares in Q3 2022, an estimated $55K.
- UBS Group first reported a position in Sierra Oncology, Inc. Common Stock in Q3 2015 and held it in 12 quarters.
- UBS Group's Sierra Oncology, Inc. Common Stock position peaked at $661K in Q2 2018.
- 1 fund tracked by Wall St. Rank held Sierra Oncology, Inc. Common Stock as of Q3 2022.
Based on UBS Group's 13F filing for Q3 2022, filed 10 Nov 2022.